8-K: Phio Pharmaceuticals Reports Year-End 2023 Financial Results and Provides Business Update

Phio Pharmaceuticals reported its 2023 year-end financial results, highlighted by progress in its PH-762 clinical trial and a strategic shift towards product development.

Summary

• Phio Pharmaceuticals reported a net loss of $10.8 million for 2023, compared to a $11.5 million loss in 2022.
• Research and development expenses decreased by 10% to $6.3 million, primarily due to reduced preclinical study costs for PH-894 and a shift towards clinical development.
• General and administrative expenses decreased by 2% to $4.4 million.
• The company's cash position was $8.5 million at the end of 2023, down from $11.8 million the previous year.
• Phio has made significant progress with its lead product candidate, PH-762, including the commencement of a Phase 1B dose escalation trial for various forms of skin cancer.
• Two patients have completed treatment in the first cohort of the PH-762 trial with no reported adverse events.
• The company has established four investigation sites for the PH-762 trial.
• Phio has also implemented a cost rationalization program, including a reduction in headcount by 36% and a move to a smaller research facility.
• The company has been granted new patents for skin-related treatments and has filed new patent applications for PH-762.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to progress in clinical trials and cost rationalization, but concerns remain about the reduced cash position and delays in the AgonOx study.

Positives

• The company has made significant progress in its clinical trial for PH-762, with two patients completing treatment without adverse events.
• Phio has secured four investigation sites for its PH-762 trial, expanding its clinical reach.
• The company has successfully reduced its net loss compared to the previous year.
• Research and development expenses have decreased, indicating a more focused approach to product development.
• New patents have been granted, strengthening the company's intellectual property portfolio.
• The company has implemented a cost rationalization program, which has reduced expenses and redirected funds to the PH-762 clinical trial.

Negatives

• The company's cash position has decreased from $11.8 million to $8.5 million.
• Further patient infusions in the AgonOx study have been delayed due to a facility renovation.
• The company has reduced its headcount by 36%, which may impact operations.
• The company has deferred further work on its PH-894 product candidate to prioritize PH-762.

Risks

• The company's cash reserves have decreased, which may require future capital raises.
• Delays in the AgonOx study due to facility renovations could impact the timeline for that program.
• The company's reliance on the success of the PH-762 clinical trial poses a significant risk.
• The company faces risks related to regulatory approvals, manufacturing, and commercialization of its product candidates.
• The company's forward-looking statements are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict.

Future Outlook

The company is focused on advancing its PH-762 clinical trials and expects the Providence Cancer Research Center to reopen in May 2024, allowing for the continuation of the AgonOx study. Phio will continue to develop its INTASYL platform and explore new applications for its technology.

Management Comments

• In 2023, we made substantial progress as a focused drug development organization.
• Our INTASYL compound PH-762 may offer an alternative which could shrink tumor size, if not eliminate the lesion, as well as reducing the extent of surgical intervention to allow for tissue sparing and facilitating a faster patient recovery.

Industry Context

Phio's focus on immuno-oncology and RNAi technology aligns with current trends in the biotechnology industry, where there is a growing interest in targeted therapies and personalized medicine. The company's work in skin cancer also addresses a significant unmet medical need, as there are limited treatment options for early-stage cutaneous squamous cell carcinoma.

Comparison to Industry Standards

• Phio's focus on RNAi technology for immuno-oncology is comparable to companies like Alnylam Pharmaceuticals and Arrowhead Pharmaceuticals, which are also developing RNA-based therapeutics.
• The company's clinical trial for PH-762 in skin cancer is similar to trials conducted by companies like Regeneron and Merck, which are also exploring immunotherapies for various cancers.
• The reported net loss of $10.8 million is within the range of losses reported by other clinical-stage biotechnology companies, but the decrease in R&D expenses and the focus on clinical development are positive signs.
• The cash position of $8.5 million is relatively low for a company in clinical trials, and may require further capital raising.

Stakeholder Impact

• Shareholders may be encouraged by the progress in clinical trials and the reduction in net loss.
• Employees may be affected by the headcount reduction, but the company's focus on clinical development may provide new opportunities.
• Patients may benefit from the development of new treatment options for skin cancer.
• Suppliers and creditors may be impacted by the company's cost rationalization program.

Next Steps

• Continue the Phase 1B clinical trial of PH-762.
• Resume patient infusions in the AgonOx study after the Providence Cancer Research Center reopens in May 2024.
• Further develop the INTASYL platform and explore new applications for the technology.

Key Dates

Keywords

PH-762, INTASYL, RNAi, immuno-oncology, clinical trial, skin cancer, biotechnology, patent, AgonOx, research and development